London (United Kingdom) – Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has received the approval for ACTAIR®, its immunotherapy tablet for the treatment of house dust mite (HDM) induced respiratory allergy, from the Australian health authorities (TGA, Therapeutic Goods Administration).
“This approval marks an important milestone for us in Australia, where we first established our presence in 2008 and have since been the market leader in allergy immunotherapy. ACTAIR®, the first HDM tablet with a demonstrated post-treatment effect registered in Australia, will complement our comprehensive product portfolio in this country for the benefit of allergic patients”, stated Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer.
As the leading allergy immunotherapy company operating directly in the country, Stallergenes Greer has a comprehensive range of subcutaneous and sublingual immunotherapy products, including ORALAIR®, STALORAL®, and ALUSTAL® which continue to be available to meet the needs of Australian patients.
ABOUT HOUSE DUST MITE INDUCED ALLERGIC RHINITIS IN AUSTRALIA
Due to its climate and the concentration of the population in coastal cities, Australia is one of the industrialized countries most affected by allergies. Allergic rhinitis is one of the most common chronic respiratory conditions, affecting around 15% of Australians. The most common causative allergens include pollens, house dust mites, moulds, and insects, of which about 40-60% of the allergic rhinitis cases are due to house dust mite.